ConductScience.org, home

Paper23901264

Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study.

Zarogoulidis K and 12 others. Drug Des Devel Ther, 2013. Cited by 36 papers, by iCite.

Cite this record

ConductScience Library. Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study. Papers, record 23901264. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23901264

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study.
PubMed
Journal
Drug Des Devel Ther
PubMed
Year
2013
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
36
iCite
Relative citation ratio, by iCite
0.89
iCite
Revised in PubMed
2021-10-21
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zarogoulidis KKonstantinos
2Ziogas EEftimios
3Boutsikou EEfimia
4Zarogoulidis PPaul
5Darwiche KKaid
6Kontakiotis TTheodoros
7Tsakiridis KKosmas
8Porpodis KKonstantinos
9Latsios DDimitrios
10Chatzizisi OOlga
11Karapantzos IIlias
12Li QQiang
13Kyriazis GGeorgios

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Interferon-alphaMajor topic
Interferon-gammaMajor topic
Lung NeoplasmsMajor topic
Small Cell Lung CarcinomaMajor topic
Female
Humans
Immunotherapy
Male
Middle Aged

Source PubMed

Download CSV of topics

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
13109738A phase I study of recombinant interferon gamma administered by s.c. injection three times per week in patients with solid tumours.Cancer Immunol Immunother1987https://conductscience.org/library/papers/3109738PubMed
222473169Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.J Clin Oncol2012https://conductscience.org/library/papers/22473169PubMed
312438449IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism.J Clin Invest2002https://conductscience.org/library/papers/12438449PubMed
41692761Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.Cancer Res1990https://conductscience.org/library/papers/1692761PubMed
52432664Angiogenic factors.Science1987https://conductscience.org/library/papers/2432664PubMed
69210707
A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.
Cancer1997https://conductscience.org/library/papers/9210707PubMed
72159055Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study.J Clin Oncol1990https://conductscience.org/library/papers/2159055PubMed
81371992The interferon system. A bird's eye view of its biochemistry.J Biol Chem1992https://conductscience.org/library/papers/1371992PubMed
911022927Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.Lancet2000https://conductscience.org/library/papers/11022927PubMed
108395259Interferon-alpha and interferon-gamma combined with chemotherapy: in vitro sensitivity studies in non-small cell lung cancer cell lines.Anticancer Drugs1993https://conductscience.org/library/papers/8395259PubMed
118108387Cytokine therapeutics: lessons from interferon alpha.Proc Natl Acad Sci U S A1994https://conductscience.org/library/papers/8108387PubMed
123296212Alfa interferon: combinations with other antineoplastic modalities.Semin Oncol1987https://conductscience.org/library/papers/3296212PubMed
136861260Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay.Cancer Chemother Pharmacol1983https://conductscience.org/library/papers/6861260PubMed
147964947Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer.J Clin Oncol1994https://conductscience.org/library/papers/7964947PubMed
157505989[Interferon therapy of the lung and locoregional therapy in pulmology].Wien Med Wochenschr1993https://conductscience.org/library/papers/7505989PubMed
169799713Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections.Semin Immunol1998https://conductscience.org/library/papers/9799713PubMed
1723386565Cancer statistics for African Americans, 2013.CA Cancer J Clin2013https://conductscience.org/library/papers/23386565PubMed
1816293867
Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial.
J Clin Oncol2005https://conductscience.org/library/papers/16293867PubMed
198882986Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomized trial.Lung Cancer1996https://conductscience.org/library/papers/8882986PubMed
208624296Selective suppression of cytokine secretion in patients with small-cell lung cancer.Ann Oncol1995https://conductscience.org/library/papers/8624296PubMed

See all 29 referencesDownload CSV of references

Cited by31

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 36 citations.

PMIDTitleJournalYearIn PapersSource
41220920IFN-gamma in the tumor microenvironment: dual roles in cancer progression and therapy.EXCLI J2025https://conductscience.org/library/papers/41220920PubMed
40473974The current and emerging immunotherapy paradigm in small-cell lung cancer.Nat Cancer2025https://conductscience.org/library/papers/40473974PubMed
36945221Molecular docking analysis of VEGF with compounds from tomato.Bioinformation2022https://conductscience.org/library/papers/36945221PubMed
35734400Homologous Recombination Pathway Alternation Predicts Prognosis of Colorectal Cancer With Chemotherapy.Front Pharmacol2022https://conductscience.org/library/papers/35734400PubMed
34685400Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer.Life (Basel)2021https://conductscience.org/library/papers/34685400PubMed
34295691Immunotherapy in small cell lung cancer: one step at a time: a narrative review.Transl Lung Cancer Res2021https://conductscience.org/library/papers/34295691PubMed
32766139Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC).Front Oncol2020https://conductscience.org/library/papers/32766139PubMed
32194311Advances and challenges in immunotherapy of small cell lung cancer.Chin J Cancer Res2020https://conductscience.org/library/papers/32194311PubMed
32102135[Research Progress of Immunotherapy and Prognostic Markers in Small Cell Lung Cancer].Zhongguo Fei Ai Za Zhi2020https://conductscience.org/library/papers/32102135PubMed
31781314The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature.Can Respir J2019https://conductscience.org/library/papers/31781314PubMed
31632972Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma.Front Cell Dev Biol2019https://conductscience.org/library/papers/31632972PubMed
31619019Technological and Therapeutic Advances in Advanced Small Cell Lung Cancer.Cancers (Basel)2019https://conductscience.org/library/papers/31619019PubMed
30643969ZWINT is the next potential target for lung cancer therapy.J Cancer Res Clin Oncol2019https://conductscience.org/library/papers/30643969PubMed
30637710The role of immunotherapy in small cell lung cancer.Clin Transl Oncol2019https://conductscience.org/library/papers/30637710PubMed
29896282Aerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease: In vivo Study. A more efficient combination.J Cancer2018https://conductscience.org/library/papers/29896282PubMed
28641701[Recent Advances and Future Strategies for Small Cell Lung Cancer].Zhongguo Fei Ai Za Zhi2017https://conductscience.org/library/papers/28641701PubMed
28456992Progress and challenges in the treatment of small cell lung cancer.Med Oncol2017https://conductscience.org/library/papers/28456992PubMed
28123595Research progress in the treatment of small cell lung cancer.J Cancer2017https://conductscience.org/library/papers/28123595PubMed
27354668The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.Oncologist2016https://conductscience.org/library/papers/27354668PubMed
27076850Tyrosine Kinase Inhibitors for the Elderly.J Cancer2016https://conductscience.org/library/papers/27076850PubMed

See all 31 cited byDownload CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23901264

GET https://conductscience.org/api/papers/v1/23901264/references?page=2